- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, May 31, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from McKnights Senior Living referenced a study to be published in the August 2024 issue of The American Journal of Managed Care® (AJMC®). The article, “Care Management Improves Total Cost of Care for Patients With Dementia,” found that a collaborative dementia care program had financial benefits in a managed Medicare population.
An article from BlackDoctor.org referenced a video interview published on AJMC.com, the website of AJMC. The interview, “Dr Chesahna Kindred Addresses Diversity Barriers in Clinical Trials,” highlighted ongoing barriers to clinical trial participation and ways to ensure Black patients are included in clinical trials for psoriasis.
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
In Study Across 15 Centers, 35% of Patients With MCL See Progression After CAR T-Cell Therapy
August 15th 2025Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression after CAR T-cell therapy, highlighting treatment challenges and outcomes.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
